<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dabrafenib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08912</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Dabrafenib mesylate is a reversible <span class="caps">ATP</span>-competitive kinase inhibitor and targets the <span class="caps">MAPK</span> pathway. <span class="caps">FDA</span> approved on May 29, 2013.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08912/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08912/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08912.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08912.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08912.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08912.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08912.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08912">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Dabrafenib Mesylate </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000036/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000036/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: YKGMKSIHIVVYKY-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 615.089165588</li>
              <li>Average Mass: 615.668</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000036">DBSALT000036</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Tafinlar </td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Weight</th><td>Average: 519.562<br>Monoisotopic: 519.101050904</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>BFSMGDJOXZAERB-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Thiazoles</td></tr><tr><th>Direct parent</th><td>Phenylthiazoles</td></tr><tr><th>Alternative parents</th><td>Sulfanilides; Benzenesulfonamides; 2,4,5-trisubstituted Thiazoles; Fluorobenzenes; Primary Aromatic Amines; Aryl Fluorides; Pyrimidines and Pyrimidine Derivatives; Sulfonyls; Sulfonamides; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>2,4,5-trisubstituted 1,3-thiazole; fluorobenzene; primary aromatic amine; aryl halide; pyrimidine; benzene; aryl fluoride; sulfonyl; sulfonamide; sulfonic acid derivative; polyamine; organohalogen; amine; primary amine; organonitrogen compound; organofluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylthiazoles. These are compounds containing a phenylthiazole moiety, which consists of an thiazole ring attacthed to a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.</td></tr><tr><th>Pharmacodynamics</th><td>Dabrafenib caused an inhibition of phosphorylated ERK. This indicates a decrease in cell proliferation. Furthermore, within 24 hours of administration, downstream mediators of the MAPK pathway were inhibited. </td></tr><tr><th>Mechanism of action</th><td>Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. </td></tr><tr><th>Absorption</th><td>After oral administration, median time to achieve peak plasma concentration (Tmax) is 2 hours. Mean absolute bioavailability of oral dabrafenib is 95%. </td></tr><tr><th>Volume of distribution</th><td><p>Apparent volume of distribution (Vd/F) = 70.3 L.<br>
Distribution to the brain is restricted because dabrafenib is a substrate and undergoes efflux by P-glycoprotein and breast cancer resistance protein.</p></td></tr><tr><th>Protein binding</th><td>99.7% bound to human plasma protein. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Dabrafenib is hepatically metabolized. The biotransformation process is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-debrafenib. This metabolite is further oxidized via CYP3A4 to form carboxy-dabrafenib and subsequently excreted in bile and urine. Carboxy-dabrafenib can also undergo decarboxylation to form desmethyl-dabrafenib, which may be reabsorbed from the gut.  Desmethyl-dabrafenib is further metabolized by CYP3A4 to oxidative metabolites.</p></td></tr><tr><th>Route of elimination</th><td>71% of the dose is excreted in feces. 23% of the dose is excreted in the urine as metabolites only. </td></tr><tr><th>Half life</th><td>Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours. </td></tr><tr><th>Clearance</th><td><p>The apparent clearance of dabrafenib is 17.0 L/h after single dosing and 34.4 L/h after 2 weeks of twice daily dosing.</p></td></tr><tr><th>Toxicity</th><td>Most common adverse reactions (&#8805;20%) for dabrafenib are hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9944</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7232</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5069</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7965</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6468</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7039</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8694</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8233</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7346</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5834</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5219</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8459</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7531</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8612</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7078
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8093
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4329 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9848
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7704
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>50 mg, 75 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Dabrafenib decreased the maximum concentration (Cmax) and area under the curve (AUC) of midazolam (a substrate of CYP3A4) by 61% and 74%, respectively. </td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00213">Pantoprazole</a></td><td>Proton pump inhibitors may alter the solubility of dabrafenib and reduce its bioavailability. </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00863">Ranitidine</a></td><td>H2-receptor antagonists may alter the solubility of dabrafenib and reduce its bioavailability. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>When taken with a fatty meal, Cmax and AUC decreased. Tmax is also prolonged compared to the fasted condition.</li></ul></td></tr></tbody></table>